Medical device company Masimo has announced that their iSpO2 Rx Pulse Oximeter will be available for Android and iOS devices, and will receive the coveted CE Mark for select countries, allowing it to be used in medical situations. The technology leverages Masimo’s SET Measure, a noninvasive monitoring platform that evaluates multiple blood constituents and physiologic parameters through motion and low perfusion pulse oximetry.
The device will enable physicians to access data about their patients directly on their smartphones or tablets, including hemoglobin levels, oxygen content, and saturation or pulse rate. It may be particularly useful for chronic obstructive pulmonary disease (COPD) patients in conducting spot checks, or asthmatics to determine the severity of an attack and the possible need to visit the hospital, for instance.
The iSpO2 Rx will include a finger pulse oximetry sensor and an optional M-LNCS reusable connector, which the company expects can be used in more than 20 sensors. The technology used is similar to the Masimo SET Measure through Motion and Low Perfusion pulse oximetry device.
The device will also feature a downloadable and upgradeable iSpO2 Rx App for clinicians. iSpO2 Rx provides real-time data, but it can also store and email up to 12 hours of diagnostic history as well.
While the announcement for the CE mark for the iSpO2 Rx is new, Masimo’s novel technology is well established in the medical industry, and is used in more than 100 million patients a year worldwide. Results from studies for the Masimo SET pulse have shown that the technology reduces ventilator weaning time and effectively measures arterial blood gas in intensive care units.